Johnson Investment Counsel Inc. boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,249 shares of the biopharmaceutical company's stock after buying an additional 2,161 shares during the quarter. Johnson Investment Counsel Inc.'s holdings in Gilead Sciences were worth $1,580,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $25,000. Activest Wealth Management grew its position in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $29,000. Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital grew its position in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the transaction, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,000 shares of company stock worth $7,632,100 over the last quarter. Company insiders own 0.27% of the company's stock.
Gilead Sciences Stock Up 0.9%
Shares of GILD opened at $118.21 on Tuesday. The stock has a market cap of $146.68 billion, a price-to-earnings ratio of 23.55, a P/E/G ratio of 0.80 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $84.34 and a 12 month high of $121.83. The company has a 50-day moving average price of $114.72 and a two-hundred day moving average price of $110.30.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the company. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Citigroup lifted their target price on Gilead Sciences from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Wednesday, October 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Finally, Cantor Fitzgerald lifted their target price on Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $118.08.
Get Our Latest Research Report on Gilead Sciences
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
